(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the fiscal year ended December 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to or Commission File Number: 001-40545 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other jurisdiction o ...

Core Insights - New real-world evidence presented at THT 2025 shows significant reductions in hospital visits and length of stay for heart failure patients after Barostim implantation [1][2] - The study highlights the clinical and economic benefits of the Barostim device, emphasizing its importance for clinicians and payers [2] Company Overview - CVRx, Inc. is a commercial-stage medical device company focused on the development and commercialization of the Barostim™ System, which is the first FDA-approved technology using neuromodulation for heart failure [3] - The Barostim device delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and alleviate heart failure symptoms [3] Study Findings - The analysis utilized data from the Premier Healthcare Database, involving 306 Barostim patients, comparing healthcare utilization before and after implantation [2] - Results indicated an 86% reduction in all-cause hospital visits, an 84% reduction in cardiovascular hospital visits, and an 85% reduction in heart failure-related hospital visits, all with p-values less than 0.0001 [4]

Core Viewpoint - CVRx (CVRX) has experienced a downtrend, losing 10.1% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom in the stock price, suggesting that selling pressure may be exhausting [2][4]. - This pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near its opening price, showing signs of support [3][4]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [4]. Fundamental Analysis - Recent upward revisions in earnings estimates for CVRX serve as a bullish indicator, correlating strongly with near-term stock price movements [6]. - The consensus EPS estimate for the current year has increased by 2.7% over the last 30 days, indicating analysts' optimism about the company's earnings potential [7]. - CVRX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

Core Viewpoint - CVRx (CVRX) shares have increased by 3.8% over the past four weeks, closing at $14.71, with a potential upside of 25.8% based on Wall Street analysts' mean price target of $18.50 [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $3.51, indicating variability among analysts; the lowest estimate suggests an 11.6% decline, while the highest predicts a 49.6% increase to $22 [2] - A tight clustering of price targets, represented by a low standard deviation, indicates a high degree of agreement among analysts regarding the stock's price movement direction [7] - The Zacks Consensus Estimate for CVRX has increased by 3.6% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [10] Group 2: Analyst Sentiment and Earnings Prospects - There is increasing optimism among analysts regarding CVRX's earnings prospects, as evidenced by strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [9] - CVRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [12]

Core Viewpoint - CVRx, Inc. reported strong financial performance in Q4 2024, driven by growth in its U.S. Heart Failure business, with total revenue reaching $15.3 million, a 36% increase compared to Q4 2023, and U.S. Heart Failure revenue growing by 41% [5]. Financial Performance - Total revenue for Q4 2024 was $15.3 million, marking a 36% year-over-year growth [5]. - Revenue from the U.S. Heart Failure segment grew by 41% compared to the same quarter in the previous year [5].

CVRx, Inc. (NASDAQ:CVRX) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, ...

CVRx, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-40545 41-1983744 (I.R.S. Employer Identification No.) 9201 West Broadway Avenue, Suite 650 Minneapolis, MN 55445 (Address of pr ...

Core Insights - CVRx, Inc. reported strong financial results for Q4 and full year 2024, with a focus on expanding its Barostim therapy for heart failure patients [3][4][15] Financial Performance - Q4 2024 revenue reached $15.3 million, a 36% increase from Q4 2023 [4] - U.S. heart failure revenue for Q4 2024 was $14.3 million, reflecting a 41% growth year-over-year [5] - Total revenue for 2024 was $51.3 million, up 31% from 2023 [15] - Gross profit for Q4 2024 was $12.8 million, a 33% increase from the previous year, with a gross margin of 83% [8][19] - The company reported a net loss of $10.7 million for Q4 2024, compared to a net loss of $9.2 million in Q4 2023 [13] Operational Highlights - Active implanting centers increased to 223 as of December 31, 2024, a 25% rise from the previous year [10][17] - The number of sales territories in the U.S. grew to 48, up from 38 in 2023 [17] - R&D expenses for Q4 2024 increased by 25% to $2.8 million, driven by clinical study costs [9] - SG&A expenses rose by 19% to $20.2 million, primarily due to increased headcount and compensation [10] Market Outlook - For Q1 2025, the company anticipates total revenue between $14.5 million and $15.0 million [26] - The full-year 2025 revenue is projected to be between $63.0 million and $65.0 million, with a gross margin between 83% and 84% [31]

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...